Stay updated with breaking news from Eva Haas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Actress Eva Noblezada talks about her personal journey in theater. Plus, a new romance book does its own spin on Shakespeare. And, public art at a local university.
Marlene (Haas) Kolling was born on May 29, 1942, to Joseph and Eva Haas. She was the 6th of 8 children born into the family. She grew up and attended school in Lefor, ND where her family had a farm. Marlene loved reading and going to dances. She met and married the love of her life, George F. Kolling, who was from Dickinson, ND. They were married on July 12, 1961, while George was in the Air Force. George and Marlene had raised three children; George who they called, Butch, Laurie and Neil. Their eldest son, Butch was born in Rapid City, SD while George was in the Air Force; Laurie and Neil we...
STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics
Published: Apr 23, 2021 LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to...
Enrollment ongoing in ENHANCE Phase 3 program Up to $30 million debt finance facility increases financial flexibility Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2020, and provides a corporate update. “2020 was a transformative year for Verona Pharma,” said David Zaccardelli, Ph...